

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/073,834	02/11/2002	David M. Koelle	G&C 30967.3-US-D1 5976	
7590 11/21/2003			EXAMINER	
Attention: Karen S. Canady			MOSHER, MARY	
Gates & Cooper LLP Howard Hughes Center, Suite 1050			ART UNIT	PAPER NUMBER
6701 Center Dr		1648		
Los Angeles, CA 90045			DATE MAILED: 11/21/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Annlinando				
	Application No.	Applicant(s)				
	10/073,834	KOELLE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mary E. Mosher, Ph.D.	1648				
The MAILING DATE of this communication appears on the cover shet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a reply be a solven, may a reply be solven, may a reply be will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDON	imely filed ays will be considered timely. m the mailing date of this communication. IED (35 U.S.C.§ 133).				
1) Responsive to communication(s) filed on	·					
2a) ☐ This action is FINAL . 2b) ☑ This	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
 4) Claim(s) 1-17,26,27 and 30-54 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-17,26,27 and 30-54 are subject to restriction and/or election requirement. 						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority documents. Copies of the certified copies of the priority application from the International Bureath * See the attached detailed Office action for a list since a specific reference was included in the first 37 CFR 1.78. a) The translation of the foreign language properties. The translation of the first sentence of the fir	ats have been received. Its have been received in Application of the certified copies not received the priority under 35 U.S.C. § 119 Its sentence of the specification of the certified copies not receive priority under 35 U.S.C. § 119 Its sentence of the specification of the priority under 35 U.S.C. § 12	ved in this National Stage ved. (e) (to a provisional application) or in an Application Data Sheet. eceived.				
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				

DETAILED ACTION

Election/Restrictions

Claims 1-17, 26, 27, 30-54 are drawn to a plurality of disclosed patentably distinct polypeptides comprising materially different amino acid sequences. The separate polypeptides bear distinct structural and/or biochemical properties, see as evidence the Roizman et al review cited in parent application 09/368,770, particularly page 850 and Figure 7. Therefore, each disclosed patentably distinct polypeptide is considered a separate invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing which inventions are obvious variants of each other or clearly admit on the record which inventions are obvious variants of each other. If the inventions are deemed obvious variants of each other, then if the examiner finds one of the inventions unpatentable over the prior art, the evidence submitted by applicant or admission of record by applicant may be used in a rejection under 35 U.S.C. §103(a) of the other inventions.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Inventions 1-5. Claims 1-6, 11, 26, 27, 30, 31, 35-38, 43-54 polypeptides and compositions, drawn to U_L19, U_L21, U_L49, gE, VP16 respectively, classified in class 424, subclass 231.1.
- Inventions 6-10 Claims 7-10, 12-17, 32-34, 39-42, 43-50 polynucleotides and compositions, drawn to U_L19, U_L21, U_L49, gE, VP16 respectively, classified in class 514, subclass 44.

The inventions are distinct, each from the other because of the following reasons:

Inventions 1-5 are drawn to structurally and functionally distinct polypeptides.

The groups of Inventions 1-5, 6-10, Inventions 1-5 are drawn to polyamino acids, Inventions 6-10 are drawn to polynucleic acids, each group involving materials with distinct structural and functional characteristics. Although the nucleic acids can be used to make the polypeptides, the polypeptides can be made by materially different methods, such as chemical synthesis or isolation from HSV-infected cells.

Claims 43-50 link groups 1-5 and 6-10, and will be examined together with either the polypeptide or the nucleic acid elected.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, divergent search requirements, and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of **one** of the inventions 1-10 to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 703-308-2926. The examiner can normally be reached on M-T and alternate F.

Application/Control Number: 10/073,834 Page 4

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4027. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

11/18/03

MARY E MOSHER
PRIMARY EXAMINER
PRIMARY EXAMINER
PRIMARY EXAMINER